Alnylam Pharmaceuticals, Inc.

ALNYNASDAQ • USD
ThemeGenomics & Precision Med.›RNA Therapeutics
304.96 USD
↗ 1.31 (0.43%)🟢PRE MARKET (AS OF 07:43 AM EDT)
🟢Market: OPEN
Open?$304.83
High?$304.95
Low?$299.29
Prev. Close?$303.64
Volume?282
Avg. Volume?1.1M
VWAP?$302.70
Rel. Volume?0.00x
Bid / Ask
Bid?$288.56 × 40
Ask?$319.19 × 40
Spread?$30.63
Midpoint?$303.88
Valuation & Ratios
Market Cap?40.5B
Shares Out?133.5M
Float?132.4M
Float %?99.9%
P/E Ratio?70.23
P/B Ratio?37.70
EPS?$4.32
Dividend?0.00%
Ex-Dividend?N/A

Alnylam Pharmaceuticals, Inc. (ALNY) trades at $304.96 per share. Technical and fundamental signals align bullish — technicals rate "Buy" while fundamentals indicate "Buy". This is driven by a robust Altman Z-Score, exceptional Return on Equity (53.7%) and a bearish Death Cross on the long-term moving averages. On the valuation front, ALNY trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Themes
Healthcare - Genomics & Precision Medicine›RNA TherapeuticsBiotech - Drug Development›Rare Disease Therapeutics
Employees
2.5K
Market Cap
39.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.alnylam.com
Listed
2004-05-28
Address
675 WEST KENDALL STREET
CAMBRIDGE, MA 02142
Phone: (617) 551-8200
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
60
Z-Score?
100
Momentum?
62
Short Sent.?
64
Piotroski F-Score?5/9Mixed
Altman Z-Score?6.22Safe
Confidence?73%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?4.08%Low
Short Interest?5.4M
Days to Cover?5.1
Free Float132.4M
Avg Daily Volume1.1M
Settlement Date2026-05-15
Financial Health
Current Ratio?3.13Strong
Quick Ratio?3.06Strong
Cash Ratio?1.27Strong
Debt/Equity?0.94Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
33/100
P/E?
Peers
100
S&P
7
70.2PRICEY▾
P/B?
Peers
100
S&P
3
37.70HIGH▾
P/S?
Peers
100
S&P
9
9.46HIGH▾
P/FCF?
Peers
100
S&P
7
63.2PRICEY▾
EV/EBITDA?
Peers
100
S&P
3
49.4HIGH▾
EV/Sales?
Peers
100
S&P
13
9.29HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
92
53.7%STRONG▾
ROA?
Peers
50
S&P
78
11.3%STRONG▾
Cash Flow & Enterprise
FCF?$641.3M
Enterprise Value?$39.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist